Lumos Diagnostics merges with RPS Diagnostics

Lumos Diagnostics, a Planet Innovation business that develops and manufactures custom rapid point-of-care (POC) diagnostic solutions, and RPS Diagnostics, a Florida-based developer and manufacturer of POC diagnostic tests, have merged to create a full-service POC diagnostic development company.

The new company, to be called Lumos Diagnostics, will continue to provide its clients complete POC development and manufacturing solutions, including access to a family of proprietary digital immunoassay readers.

In addition, Lumos Diagnostics will focus on the international launch of the FebriDx test, a world-first rapid point-of-care test that can differentiate a viral from bacterial infection in patients with Acute Respiratory Infection. Physicians are currently unable to easily distinguish bacterial from viral infections, which has led to the global problem of over-prescription of antibiotics. FebriDx enables doctors to get a result in under 10 minutes, empowering them to make more informed decisions when treating patients.

Sam Lanyon, Chairman of the Board of Lumos Diagnostics and Co-CEO of PI, said: “This is a very exciting time for Lumos Diagnostics. We had always planned to develop our own line of products in parallel with our services business, but this merge with RPS Diagnostics has enabled us to fast track that progress. We have evaluated many technologies over the years, and believe that combining RPS Diagnostics’ novel biomarker technology and commercial experience together with Lumos Diagnostics’ reader-based platform results in a highly strategic and synergistic union that will support a robust pipeline and commercial success.”

Dr Robert Sambursky, former President and CEO of RPS Diagnostics, has taken on the role of CEO of Lumos Diagnostics, with Eric Perrault as Chief Commercial Officer and Sacha Dopheide as Chief Technology Officer. The teams from both previous companies have been retained as the staff have complementary skills, with very little overlap of roles.

Dr Sambursky said: “Using FebriDx to help triage outpatient ARI is a game changer because successful antibiotic stewardship requires the clinician to first rule out a clinically significant bacterial infection. In addition, access to novel Lumos Diagnostics reader technology will facilitate next generation digital enhancements which will accelerate speed to results, allow for quantitation, and enhance objectivity of our branded product lines.”

Visit the Lumos Diagnostics website